Billionaire Bass Moves Beyond Biosphere 2

As his radical ecology experiment meets with criticism, even ridicule, he shows more interest in mainstream science Texas billionaire Edward Bass, best known for his bankrolling of Biosphere 2, now appears to be focusing his largess a bit closer to the scientific mainstream. The Biosphere 2 project, an experiment set up near Tucson, Ariz., attempting to establish a sealed, self-sustaining, three-acre module with eight humans inside, has taken a beating from the press and scientists over its la

Written byScott Veggeberg
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Edward Bass is 46 years old and--as heir to a fortune that originated with his great-uncle Sid Richardson, a Texas oil wildcatter--is one of the wealthiest men in the United States. But although many of his siblings' interests run more toward luxury and high-stakes business ventures, he prefers a down-to- earth lifestyle. He drives his own car, flies commercial airlines, and doesn't spend a lot of money on fancy houses, says his publicist, Terrell Lamb. He is also one of the largest benefactors of environmental research in the world, not all of which attract as much interest--and derision--as Biosphere 2. Besides funding Biosphere 2 and the Yale Institute for Biospheric Studies, Bass is on the board of the World Wildlife Fund (WWF); the New York Botanical Garden; the African Wildlife Foundation; and the Jane Goodall Institute for Wildlife Research, Education and Conservation. In a July 1992 article in Vanity Fair, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies